A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.
A study that aims to quantify the state of DAA uptake and its impact on the HCV epidemic among PLWH in San Diego, and to characterize negative predictors of DAA treatment uptake among PLWH in San Diego. Retrospective and prospective data from UCSD Owen Clinic will be utilized to calculate HCV prevalence, primary incidence, and reinfection incidence. Using mathematical epidemic models, the study will assess levels of existing and scaled-up interventions necessary for HCV elimination from PLWH in San Diego.
Study Type
OBSERVATIONAL
Enrollment
450
Owen Clinic-University of California, San Diego
San Diego, California, United States
RECRUITINGAnnual proportion of HIV-infected patients who initiate direct acting antivirals
Time frame: 2014-2020
Annual proportion of PLWH co-infected with HCV who are treatment naïve, previously treated with no sustained virologic response (SVR), or re-infected post-SVR
Time frame: 2008-2020
Annual HCV chronic prevalence, primary incidence, and reinfection incidence among HIV-infected patients
Time frame: 2008-2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.